Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2017 · 10-Q
Revenue$4.22M$4.22M−43.2% vs Q2 2016 Net Income-$2.76M-$2.76MN/M vs Q2 2016 EPS Diluted-$0.07-$0.07— vs Q2 2016 Gross Profit$2,262,769−45.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,511,316N/M Free Cash Flowderived-$5,644,396N/M Margins · derivedGross margin53.6%−2.0 pt vs Q2 2016
Operating margin-64.5%−69.5 pt vs Q2 2016
Net margin-65.5%−64.4 pt vs Q2 2016
ended Jul 1, 2017 · filed Aug 10, 2017 · 40 d after period end